Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.26
CYAN's Cash to Debt is ranked lower than
91% of the 858 Companies
in the Global Biotechnology industry.

( Industry Median: 68.31 vs. CYAN: 0.26 )
Ranked among companies with meaningful Cash to Debt only.
CYAN' s 10-Year Cash to Debt Range
Min: 0.06  Med: 0.69 Max: 8.91
Current: 0.26
0.06
8.91
Equity to Asset 0.68
CYAN's Equity to Asset is ranked higher than
50% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CYAN: 0.68 )
Ranked among companies with meaningful Equity to Asset only.
CYAN' s 10-Year Equity to Asset Range
Min: 0.65  Med: 0.77 Max: 0.92
Current: 0.68
0.65
0.92
F-Score: 7
Z-Score: 3.37
M-Score: -2.58
WACC vs ROIC
8.42%
1.21%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 3.73
CYAN's Operating margin (%) is ranked higher than
72% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: -71.95 vs. CYAN: 3.73 )
Ranked among companies with meaningful Operating margin (%) only.
CYAN' s 10-Year Operating margin (%) Range
Min: -75.43  Med: 0.76 Max: 32.46
Current: 3.73
-75.43
32.46
Net-margin (%) 0.84
CYAN's Net-margin (%) is ranked higher than
69% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: -68.66 vs. CYAN: 0.84 )
Ranked among companies with meaningful Net-margin (%) only.
CYAN' s 10-Year Net-margin (%) Range
Min: -76.68  Med: -0.37 Max: 36.84
Current: 0.84
-76.68
36.84
ROE (%) 1.33
CYAN's ROE (%) is ranked higher than
75% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. CYAN: 1.33 )
Ranked among companies with meaningful ROE (%) only.
CYAN' s 10-Year ROE (%) Range
Min: -66.15  Med: -0.96 Max: 27.54
Current: 1.33
-66.15
27.54
ROA (%) 0.91
CYAN's ROA (%) is ranked higher than
77% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: -26.75 vs. CYAN: 0.91 )
Ranked among companies with meaningful ROA (%) only.
CYAN' s 10-Year ROA (%) Range
Min: -54  Med: -0.67 Max: 22.08
Current: 0.91
-54
22.08
ROC (Joel Greenblatt) (%) 6.56
CYAN's ROC (Joel Greenblatt) (%) is ranked higher than
77% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: -365.20 vs. CYAN: 6.56 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CYAN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -70.18  Med: 1.10 Max: 34.74
Current: 6.56
-70.18
34.74
Revenue Growth (3Y)(%) 11.30
CYAN's Revenue Growth (3Y)(%) is ranked higher than
68% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. CYAN: 11.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CYAN' s 10-Year Revenue Growth (3Y)(%) Range
Min: -9.7  Med: 2.70 Max: 18.7
Current: 11.3
-9.7
18.7
EBITDA Growth (3Y)(%) -24.50
CYAN's EBITDA Growth (3Y)(%) is ranked lower than
76% of the 432 Companies
in the Global Biotechnology industry.

( Industry Median: -4.40 vs. CYAN: -24.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CYAN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -26.6  Med: 13.80 Max: 122.4
Current: -24.5
-26.6
122.4
EPS Growth (3Y)(%) -100.00
CYAN's EPS Growth (3Y)(%) is ranked lower than
99% of the 420 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. CYAN: -100.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CYAN' s 10-Year EPS Growth (3Y)(%) Range
Min: -100  Med: -9.40 Max: 44.2
Current: -100
-100
44.2
» CYAN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

CYAN Guru Trades in Q3 2014

Jim Simons 71,400 sh (+3.93%)
» More
Q4 2014

CYAN Guru Trades in Q4 2014

Jim Simons 75,300 sh (+5.46%)
» More
Q1 2015

CYAN Guru Trades in Q1 2015

Jim Simons 80,800 sh (+7.30%)
» More
Q2 2015

CYAN Guru Trades in Q2 2015

Jim Simons 89,800 sh (+11.14%)
» More
» Details

Insider Trades

Latest Guru Trades with CYAN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 188.52
CYAN's P/E(ttm) is ranked lower than
87% of the 216 Companies
in the Global Biotechnology industry.

( Industry Median: 36.10 vs. CYAN: 188.52 )
Ranked among companies with meaningful P/E(ttm) only.
CYAN' s 10-Year P/E(ttm) Range
Min: 5.21  Med: 10.69 Max: 422
Current: 188.52
5.21
422
Forward P/E 14.99
CYAN's Forward P/E is ranked higher than
77% of the 164 Companies
in the Global Biotechnology industry.

( Industry Median: 22.73 vs. CYAN: 14.99 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 175.50
CYAN's PE(NRI) is ranked lower than
88% of the 214 Companies
in the Global Biotechnology industry.

( Industry Median: 35.00 vs. CYAN: 175.50 )
Ranked among companies with meaningful PE(NRI) only.
CYAN' s 10-Year PE(NRI) Range
Min: 5.33  Med: 10.65 Max: 256.25
Current: 175.5
5.33
256.25
P/B 2.01
CYAN's P/B is ranked higher than
82% of the 751 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. CYAN: 2.01 )
Ranked among companies with meaningful P/B only.
CYAN' s 10-Year P/B Range
Min: 0.63  Med: 1.40 Max: 3.68
Current: 2.01
0.63
3.68
P/S 1.27
CYAN's P/S is ranked higher than
95% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.19 vs. CYAN: 1.27 )
Ranked among companies with meaningful P/S only.
CYAN' s 10-Year P/S Range
Min: 0.42  Med: 1.06 Max: 2.64
Current: 1.27
0.42
2.64
POCF 35.14
CYAN's POCF is ranked higher than
51% of the 202 Companies
in the Global Biotechnology industry.

( Industry Median: 32.56 vs. CYAN: 35.14 )
Ranked among companies with meaningful POCF only.
CYAN' s 10-Year POCF Range
Min: 4.46  Med: 13.75 Max: 100
Current: 35.14
4.46
100
EV-to-EBIT 37.37
CYAN's EV-to-EBIT is ranked lower than
54% of the 229 Companies
in the Global Biotechnology industry.

( Industry Median: 27.86 vs. CYAN: 37.37 )
Ranked among companies with meaningful EV-to-EBIT only.
CYAN' s 10-Year EV-to-EBIT Range
Min: -170.9  Med: 10.30 Max: 139.3
Current: 37.37
-170.9
139.3
Shiller P/E 23.43
CYAN's Shiller P/E is ranked higher than
84% of the 113 Companies
in the Global Biotechnology industry.

( Industry Median: 44.53 vs. CYAN: 23.43 )
Ranked among companies with meaningful Shiller P/E only.
CYAN' s 10-Year Shiller P/E Range
Min: 11.32  Med: 14.68 Max: 74.71
Current: 23.43
11.32
74.71
Current Ratio 2.34
CYAN's Current Ratio is ranked lower than
70% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. CYAN: 2.34 )
Ranked among companies with meaningful Current Ratio only.
CYAN' s 10-Year Current Ratio Range
Min: 1.13  Med: 3.36 Max: 8.33
Current: 2.34
1.13
8.33
Quick Ratio 1.16
CYAN's Quick Ratio is ranked lower than
80% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.01 vs. CYAN: 1.16 )
Ranked among companies with meaningful Quick Ratio only.
CYAN' s 10-Year Quick Ratio Range
Min: 0.54  Med: 1.87 Max: 7.93
Current: 1.16
0.54
7.93
Days Inventory 105.31
CYAN's Days Inventory is ranked higher than
56% of the 410 Companies
in the Global Biotechnology industry.

( Industry Median: 120.98 vs. CYAN: 105.31 )
Ranked among companies with meaningful Days Inventory only.
CYAN' s 10-Year Days Inventory Range
Min: 59.68  Med: 88.14 Max: 178.35
Current: 105.31
59.68
178.35
Days Sales Outstanding 38.13
CYAN's Days Sales Outstanding is ranked higher than
71% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. CYAN: 38.13 )
Ranked among companies with meaningful Days Sales Outstanding only.
CYAN' s 10-Year Days Sales Outstanding Range
Min: 30  Med: 58.01 Max: 89.65
Current: 38.13
30
89.65

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 25.96
CYAN's Price/Net Current Asset Value is ranked lower than
87% of the 537 Companies
in the Global Biotechnology industry.

( Industry Median: 6.85 vs. CYAN: 25.96 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CYAN' s 10-Year Price/Net Current Asset Value Range
Min: 2.21  Med: 8.11 Max: 600
Current: 25.96
2.21
600
Price/Tangible Book 1.88
CYAN's Price/Tangible Book is ranked higher than
86% of the 693 Companies
in the Global Biotechnology industry.

( Industry Median: 5.31 vs. CYAN: 1.88 )
Ranked among companies with meaningful Price/Tangible Book only.
CYAN' s 10-Year Price/Tangible Book Range
Min: 0.5  Med: 1.44 Max: 15.84
Current: 1.88
0.5
15.84
Price/Projected FCF 4.91
CYAN's Price/Projected FCF is ranked lower than
55% of the 158 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. CYAN: 4.91 )
Ranked among companies with meaningful Price/Projected FCF only.
CYAN' s 10-Year Price/Projected FCF Range
Min: 0.76  Med: 1.66 Max: 6.4
Current: 4.91
0.76
6.4
Price/Median PS Value 1.14
CYAN's Price/Median PS Value is ranked lower than
51% of the 544 Companies
in the Global Biotechnology industry.

( Industry Median: 1.08 vs. CYAN: 1.14 )
Ranked among companies with meaningful Price/Median PS Value only.
CYAN' s 10-Year Price/Median PS Value Range
Min: 0.47  Med: 1.33 Max: 24
Current: 1.14
0.47
24
Price/Graham Number 3.45
CYAN's Price/Graham Number is ranked lower than
51% of the 169 Companies
in the Global Biotechnology industry.

( Industry Median: 3.18 vs. CYAN: 3.45 )
Ranked among companies with meaningful Price/Graham Number only.
CYAN' s 10-Year Price/Graham Number Range
Min: 0.56  Med: 1.40 Max: 24.06
Current: 3.45
0.56
24.06
Earnings Yield (Greenblatt) (%) 2.64
CYAN's Earnings Yield (Greenblatt) (%) is ranked higher than
85% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. CYAN: 2.64 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CYAN' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.7  Med: 7.00 Max: 18.8
Current: 2.64
0.7
18.8
Forward Rate of Return (Yacktman) (%) 2.07
CYAN's Forward Rate of Return (Yacktman) (%) is ranked lower than
69% of the 100 Companies
in the Global Biotechnology industry.

( Industry Median: 13.39 vs. CYAN: 2.07 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
CYAN' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -3  Med: 1.10 Max: 37.2
Current: 2.07
-3
37.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Cyanotech Corp was incorporated in 1983. The Company cultivates and produces natural products derived from microalgae for the nutritional supplements market. Its products include Hawaiian Spirulina Pacifica - a nutrient-rich dietary supplement used for extra energy, a strengthened immune system, cardiovascular benefits and as a source of antioxidant carotenoids; and Hawaiian BioAstin natural astaxanthin - a powerful dietary antioxidant shown to support and maintain the body's natural inflammatory response, to enhance skin, and to support eye and joint health. It has expanding applications as a human nutraceutical and functional food ingredient. The Spirulina Pacifica is produced in two forms powder and tablets, and BioAstin is produced in three forms a liquid lipid extract, gelcaps and microencapsulated beadlets. Its products are marketed and sold in bulk quantities to manufacturers, formulators and distributors in the health foods and nutritional supplements markets and as packaged consumer products to distributors, retailers and direct consumers. The Company' has four United States patents in force: one on aspects of its production methods and three for use of its BioAstin products. The Company's competitors include Dainippon Ink and Chemical Company's Earthrise facility in California, Parry Nutraceuticals, a division of Murugappa Group of India and several farms in China. Several governmental agencies regulate various aspects of the company's business and its products in the United States, including the Food and Drug Administration, the Federal Trade Commission, the Consumer Product Safety Commission, the State of Hawaii Department of Health, the Department of Agriculture, the Environmental Protection Agency, the United States Postal Service, state attorney general offices and various agencies of the states and localities in which the company's products are sold.
» More Articles for CYAN

Headlines

Articles On GuruFocus.com
Cyanotech Corp. Reports Operating Results (10-Q) Feb 11 2011 
Cyanotech Corp. Reports Operating Results (10-Q) Nov 10 2010 
Cyanotech Corp. Reports Operating Results (10-K) Jun 24 2010 
Cyanotech Corp. Reports Operating Results (10-Q) Feb 11 2010 
Cyanotech Corp. Reports Operating Results (10-Q) Nov 12 2009 
Cyanotech Corp. Reports Operating Results (10-Q) Aug 13 2009 
Cyanotech Corp. Reports Operating Results (10-Q) Feb 13 2009 

More From Other Websites
CYANOTECH CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... Aug 26 2015
Cyanotech Corp. Q1 Earnings, 2015 Aug 25 2015
CYANOTECH CORP Financials Aug 19 2015
Nutrex Hawaii Announces New Gluten-Free, Grass Free Green Complete® Superfood Powder Aug 18 2015
Cyanotech reports lower quarterly loss, expands Costco distribution Aug 10 2015
CYANOTECH CORP Files SEC form 10-Q, Quarterly Report Aug 07 2015
Cyanotech Reports Financial Results for the First Quarter of Fiscal Year 2016 Aug 07 2015
Hawaii's Cyanotech posts $24k loss on $34M in sales in FY 2015 Jul 16 2015
Cyanotech Reports Financial Results for the Fourth Quarter and Fiscal Year 2015 Jul 15 2015
CYANOTECH CORP Files SEC form 10-K, Annual Report Jul 15 2015
Cyanotech Announces Delayed Filing of Annual Financial Statements Jun 29 2015
Cyanotech Adds Astaxanthin Productivity Enhancement Jun 12 2015
CYANOTECH CORP Files SEC form 10-Q, Quarterly Report Feb 12 2015
Cyanotech Reports Financial Results for the Third Quarter and First Nine Months of Fiscal Year 2015 Feb 12 2015
CYANOTECH CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Jan 28 2015
Cyanotech Names David L. Vied as a Director Jan 28 2015
CYANOTECH CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 19 2014
Cyanotech Reports Litigation Resolved Dec 19 2014
CYANOTECH CORP Files SEC form 10-Q, Quarterly Report Nov 12 2014
Cyanotech Reports Financial Results for the Second Quarter and First Half of Fiscal Year 2015 Nov 10 2014
Cyanotech Adds 2,280 Solar Array Panels; Reduces Greenhouse Emissions by 791 Metric Tons of Carbon... Oct 31 2014
CYANOTECH CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Sep 02 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK